Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials
Ann Rheum Dis 2024 doi: 10.1136/ard-2024-225933 Epub ahead of print
In a large pool of Phase 2b/3 trial data, the incidence rate of uveitis with bimekizumab over 2034.4 patient years (PYs) remained low at 1.2/100 PYs, suggesting bimekizumab may be an appropriate treatment option for patients with axSpA and uveitis. Compared with placebo, bimekizumab had a lower incidence rate of uveitis in patients with and without a history of uveitis.
Brown, et al. pooled data from BE MOBILE 1, BE MOBILE 2, BE AGILE, and their open-label extension studies to determine the incidence of uveitis in patients with axSpA that were treated with bimekizumab or placebo.
Keywords:
